|

Vevoctadekin Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Engineered IL-18 Variant ST-067, Engineered Interleukin-18 Variant ST-067, ST 067, ST-067, ST067 +1 more

Pipeline

Phase 1/2: 1

Top Sponsors

  • Fred Hutchinson Cancer Center1

Indications

  • Refractory Primary Mediastinal Large B-Cell Lymphoma1
  • Refractory Indolent B-Cell Non-Hodgkin Lymphoma1
  • Refractory High-Grade B-Cell Lymphoma1
  • Refractory Grade 3b Follicular Lymphoma1
  • Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified1

Seattle, Washington1 trial

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.